Last reviewed · How we verify

NCT05279469: COVID-19

D-Dimer as Predictor of Disease Outcome in Intensive Care Unit in COVID-19m Patients

Completed Last updated 15 March 2022
What this trial tests

trial testing no intervention, just observational for D-Dimer level in blood in Critical Illness in 465 participants. Completed in 9 March 2022.

Timeline
10 June 2021
Primary endpoint
3 March 2022
9 March 2022

Quick facts

Lead sponsorAin Shams University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment465
Start date10 June 2021
Primary completion3 March 2022
Estimated completion9 March 2022
Sites2 locations across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Eligibility, any sex, with Critical Illness or Pneumonia, Viral. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluating value of D-Dimer blood level of icu admitted patients on admission and 48 hours later as outcome predictor in SARS.COV.2 patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Critical Illness

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05279469.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing